Diana Moss, Apr 29, 2010
The recent flurry of publicity in transgenic (also known as genetically modified or “GM”) seed reveals a broader controversy over competition policy in high technology industries. What constitutes conduct by a patent-holder that is legitimately within its rights, versus what exceeds the scope of a patent? More specifically, how should antitrust deal with a patent-holder that is also a dominant firm, and alleged to have maintained or leveraged its monopoly by
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 18.227.161.176
Please verify email or join us to access premium content!